Mark de Caestecker
Associate Professor of Medicine
Last active: 10/23/2018

Bridging Translation by Improving Preclinical Study Design in AKI.

de Caestecker M, Humphreys BD, Liu KD, Fissell WH, Cerda J, Nolin TD, Askenazi D, Mour G, Harrell FE, Pullen N, Okusa MD, Faubel S, ASN AKI Advisory Group
J Am Soc Nephrol. 2015 26 (12): 2905-16

PMID: 26538634 · PMCID: PMC4657852 · DOI:10.1681/ASN.2015070832

Despite extensive research, no therapeutic interventions have been shown to prevent AKI, accelerate recovery of AKI, or reduce progression of AKI to CKD in patients. This failure in translation has led investigators to speculate that the animal models being used do not predict therapeutic responses in humans. Although this issue continues to be debated, an important concern that has not been addressed is whether improvements in preclinical study design can be identified that might also increase the likelihood of translating basic AKI research into clinical practice using the current models. In this review, we have taken an evidence-based approach to identify common weaknesses in study design and reporting in preclinical AKI research that may contribute to the poor translatability of the findings. We focused on use of N-acetylcysteine or sodium bicarbonate for the prevention of contrast-induced AKI and use of erythropoietin for the prevention of AKI, two therapeutic approaches that have been extensively studied in clinical trials. On the basis of our findings, we identified five areas for improvement in preclinical study design and reporting. These suggested and preliminary guidelines may help improve the quality of preclinical research for AKI drug development.

Copyright © 2015 by the American Society of Nephrology.

MeSH Terms (11)

Acetylcysteine Acute Kidney Injury Animals Contrast Media Disease Models, Animal Erythropoietin Free Radical Scavengers Humans Research Design Sodium Bicarbonate Translational Medical Research

Connections (2)

This publication is referenced by other Labnodes entities:

Links